search
Back to results

Treatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine

Primary Purpose

Malaria

Status
Completed
Phase
Phase 4
Locations
Gabon
Study Type
Interventional
Intervention
Quinine plus sulfadoxine-pyrimethamine
Sponsored by
Albert Schweitzer Hospital
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Malaria focused on measuring Malaria, Quinine, Sulfadoxine-pyrimethamine, Gabon

Eligibility Criteria

2 Years - 7 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Uncomplicated falciparum malaria Asexual parasitaemia between 20,000 and 200,000/µL No mixed plasmodial infection Fever with temperature above 38 °C or history of fever during the preceding 24 hours No effective anti-malarial treatment for the present attack Informed consent Exclusion Criteria: Haemoglobin < 7 g/dL Packed-cell volume < 20% White cell count > 16,000/µL Platelet count < 40,000/µL Schizontaemia > 50/µL Impaired consciousness Convulsions or history of convulsions Concomitant diseases masking assessment of response

Sites / Locations

  • Medical Research Unit, Lambaréné

Outcomes

Primary Outcome Measures

Proportion of cured patients by day 28

Secondary Outcome Measures

Proportion of gametocytes carriers during the hospitalisation period and on days 7, 14, 21, and 28
Parasite clearance time
Fever clearance time
Assessment of adverse events during the study period

Full Information

First Posted
September 11, 2005
Last Updated
September 19, 2005
Sponsor
Albert Schweitzer Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT00167739
Brief Title
Treatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine
Official Title
Short Course of Quinine Plus a Single Dose of Sulphadoxine-Pyrimethamine for Plasmodium Falciparum Malaria
Study Type
Interventional

2. Study Status

Record Verification Date
September 2005
Overall Recruitment Status
Completed
Study Start Date
April 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
February 2004 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Albert Schweitzer Hospital

4. Oversight

5. Study Description

Brief Summary
Quinine remains the treatment of choice of hospitalised malaria cases. The long treatment duration of 7 days, and adverse reactions often hamper its adequate use. Reducing the treatment duration by adding sulfadoxine-pyrimethamine may enhance compliance and reduce side effects. The efficacy of a 3-day treatment of quinine plus sulfadoxine-pyrimethamine for the treatment of hospitalised, uncomplicated malaria cases was assessed.
Detailed Description
One main concern of clinicians in malaria endemic areas is to find a simple malaria treatment with short treatment duration. The concept of combination therapy, which may reduce treatment duration and delay the spread of drug resistance in addition to an increase in efficacy, has been therefore introduced. In contrast to the outpatient treatment of malaria where emergence of resistance has lead to new drugs policies, the treatment of hospitalised malaria cases remains, in many endemic countries, intravenous quinine for 7 days. The efficacy of this regimen is well established throughout Africa. The effectiveness of the quinine treatment may be considerably lower because of discontinuation of treatment due to early discharge, the occurrence of side effects or because of the fact that patients feel better and stop the treatment. Therefore, sulfadoxine-pyrimethamine (SP) is often added at discharge. This regimen has been shown to be effective. But in Africa, where the practice seems widespread, it has been assessed in only two trials. Since resistance of Plasmodium falciparum to SP is increasing rapidly in Africa and there is evidence that SP monotherapy induce gametocytaemia, we hypothesize that the combination quinine/SP increases SP efficacy and prevents induction of gametocytaemia. In addition, since the use of the full course of quinine therapy may be hampered by many factors (hospital cost, hospitalisation duration, availability of beds, compliance and side effects), the addition of the long acting SP to complete a short course of quinine treatment may prevent recrudescence or reinfection and may increase effectiveness of malaria treatment and reduce postdischarge morbidity. The efficacy and safety of the short course of intravenous quinine (3-day treatment) plus a single dose of oral SP for the treatment of falciparum malaria was investigated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malaria
Keywords
Malaria, Quinine, Sulfadoxine-pyrimethamine, Gabon

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
50 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Quinine plus sulfadoxine-pyrimethamine
Primary Outcome Measure Information:
Title
Proportion of cured patients by day 28
Secondary Outcome Measure Information:
Title
Proportion of gametocytes carriers during the hospitalisation period and on days 7, 14, 21, and 28
Title
Parasite clearance time
Title
Fever clearance time
Title
Assessment of adverse events during the study period

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
7 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Uncomplicated falciparum malaria Asexual parasitaemia between 20,000 and 200,000/µL No mixed plasmodial infection Fever with temperature above 38 °C or history of fever during the preceding 24 hours No effective anti-malarial treatment for the present attack Informed consent Exclusion Criteria: Haemoglobin < 7 g/dL Packed-cell volume < 20% White cell count > 16,000/µL Platelet count < 40,000/µL Schizontaemia > 50/µL Impaired consciousness Convulsions or history of convulsions Concomitant diseases masking assessment of response
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michel A. Missinou, PhD
Organizational Affiliation
Albert Schweitzer Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical Research Unit, Lambaréné
City
Lambaréné
State/Province
Moyen Ogooué
ZIP/Postal Code
B.P. 118
Country
Gabon

12. IPD Sharing Statement

Citations:
PubMed Identifier
8106787
Citation
Kremsner PG, Winkler S, Brandts C, Neifer S, Bienzle U, Graninger W. Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon. J Infect Dis. 1994 Feb;169(2):467-70. doi: 10.1093/infdis/169.2.467.
Results Reference
background
PubMed Identifier
15183620
Citation
Alloueche A, Bailey W, Barton S, Bwika J, Chimpeni P, Falade CO, Fehintola FA, Horton J, Jaffar S, Kanyok T, Kremsner PG, Kublin JG, Lang T, Missinou MA, Mkandala C, Oduola AM, Premji Z, Robertson L, Sowunmi A, Ward SA, Winstanley PA. Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Lancet. 2004 Jun 5;363(9424):1843-8. doi: 10.1016/S0140-6736(04)16350-2.
Results Reference
background
PubMed Identifier
12753638
Citation
Bousema JT, Gouagna LC, Meutstege AM, Okech BE, Akim NI, Githure JI, Beier JC, Sauerwein RW. Treatment failure of pyrimethamine-sulphadoxine and induction of Plasmodium falciparum gametocytaemia in children in western Kenya. Trop Med Int Health. 2003 May;8(5):427-30. doi: 10.1046/j.1365-3156.2003.01047.x.
Results Reference
background
PubMed Identifier
15262108
Citation
Kremsner PG, Krishna S. Antimalarial combinations. Lancet. 2004 Jul 17-23;364(9430):285-94. doi: 10.1016/S0140-6736(04)16680-4.
Results Reference
background
PubMed Identifier
11544977
Citation
Athan E, Durrheim DN, Barnes K, Mngomezulu NM, Mabuza A, Govere J. Effectiveness of short-course quinine and single-dose sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria in Mpumalanga Province, South Africa. S Afr Med J. 2001 Jul;91(7):592-4.
Results Reference
background
PubMed Identifier
11816441
Citation
Rahman MR, Paul DC, Rashid M, Ghosh A, Bangali AM, Jalil MA, Faiz MA. A randomized controlled trial on the efficacy of alternative treatment regimens for uncomplicated falciparum malaria in a multidrug-resistant falciparum area of Bangladesh--narrowing the options for the National Malaria Control Programme? Trans R Soc Trop Med Hyg. 2001 Nov-Dec;95(6):661-7. doi: 10.1016/s0035-9203(01)90108-7.
Results Reference
background
PubMed Identifier
15860096
Citation
Ogutu BR, Nzila AM, Ochong E, Mithwani S, Wamola B, Olola CH, Lowe B, Kokwaro GO, Marsh K, Newton CR. The role of sequential administration of sulphadoxine/pyrimethamine following quinine in the treatment of severe falciparum malaria in children. Trop Med Int Health. 2005 May;10(5):484-8. doi: 10.1111/j.1365-3156.2005.01415.x.
Results Reference
background
PubMed Identifier
10897366
Citation
Deloron P, Mayombo J, Le Cardinal A, Mezui-Me-Ndong J, Bruzi-Baert C, Lekoulou F, Elissa N. Sulfadoxine-pyrimethamine for the treatment of Plasmodium falciparum malaria in Gabonese children. Trans R Soc Trop Med Hyg. 2000 Mar-Apr;94(2):188-90. doi: 10.1016/s0035-9203(00)90272-4.
Results Reference
background
PubMed Identifier
1093610
Citation
Hall AP, Doberstyn EB, Mettaprakong V, Sonkom P. Falciparum malaria cured by quinine followed by sulfadoxine-pyrimethamine. Br Med J. 1975 Apr 5;2(5961):15-7. doi: 10.1136/bmj.2.5961.15.
Results Reference
background
PubMed Identifier
326337
Citation
Hall AP, Doberstyn EB, Karnchanachetanee C, Samransamruajkit S, Laixuthai B, Pearlman EJ, Lampe RM, Miller CF, Phintuyothin P. Sequential treatment with quinine and mefloquine or quinine and pyrimethamine-sulfadoxine for falciparum malaria. Br Med J. 1977 Jun 25;1(6077):1626-8. doi: 10.1136/bmj.1.6077.1626.
Results Reference
background
PubMed Identifier
3899397
Citation
de Souza JM, Sheth UK, de Oliveira RM, Roulet H, de Souza SD. An open, randomized, phase III clinical trial of mefloquine and of quinine plus sulfadoxine-pyrimethamine in the treatment of symptomatic falciparum malaria in Brazil. Bull World Health Organ. 1985;63(3):603-9.
Results Reference
background
Links:
URL
http://www.malaria.org
Description
General information on malaria at the website of the Malaria Foundation International
URL
http://www.lambarene.org
Description
Homepage of the Medical Research unit, Lambarene

Learn more about this trial

Treatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine

We'll reach out to this number within 24 hrs